Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Moermans (Liege, Belgium), S. Graff (Liege, Belgium), L. Medard (Liege, Belgium), F. Schleich (Liege, Belgium), V. Paulus (Liege, Belgium), F. Guissard (Liege, Belgium), M. Henket (Liege, Belgium), R. Louis (Liege, Belgium). Clinical trial: Impact of Probiotical® on asthma control and inflammation. 5281

Member's Comments

No comment yet.

Related content which might interest you: Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Aerobic training decrease bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: A randomized controlled trial Source: International Congress 2014 – Best abstracts in pulmonary rehabilitation and exercise training Year: 2014 Correlation between meteo-climatological factors and asthma exacerbation among children: A prospective study Source: International Congress 2016 – Living with asthma around the globe Year: 2016 Detection of asthma patient-reported exacerbations during follow-up in the ASTROLAB cohort Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Evaluation of vitamin D in bronchial asthma and the effect of vitamin D supplementation on asthma severity and control: A randomised control trial Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Aerobic training decreases bronchial hyperresponsiveness, serum chemokines and symptoms in asthmatic patients: Randomized controlled trial Source: Annual Congress 2013 –Rehabilitation, exercise and adjunct physiotherapy techniques in different respiratory conditions Year: 2013 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 The control of asthma in real life: Baseline evaluation of a long-term study Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Effect of allergic sensitization on clinical course of patients with COPD in the Hokkaido COPD cohort study Source: International Congress 2014 – COPD physiopathology Year: 2014 4–year trajectory of medication adherence amongst severe asthma patients: Risk factors and impact on asthma control Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013